Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Bunge Global $2 billion senior notes offering
The investment-grade notes are due 2028, 2029 and 2034
Province of Ontario $2 billion global bond offering
The investment-grade bonds are due 2029
MBX Biosciences $188 million IPO
The shares are listed on the Nasdaq Global Select Market
W.W. Grainger $500 million notes offering
The investment-grade notes are due 2034
Terns Pharmaceuticals $173 million stock and pre-funded warrants offering
The shares are listed on the Nasdaq Global Select Market
Ionis Pharmaceuticals $500.3 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
PG&E $1 billion fixed-to-fixed reset rate junior subordinated notes offering
The 7.375% fixed-to-fixed reset rate junior subordinated notes are due 2055
XCHG IPO
We advised XCHG on its IPO and Nasdaq listing
Payoneer Global tender offer for warrants
We advised Payoneer on the tender offer
Banco de Crédito del Perú $600 million subordinated notes offering
We advised BCP on the takedown under its MTN program